286 related articles for article (PubMed ID: 34588093)
1. Novel antidepressant drugs: Beyond monoamine targets.
Gonda X; Dome P; Neill JC; Tarazi FI
CNS Spectr; 2023 Feb; 28(1):6-15. PubMed ID: 34588093
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.
Jha MK; Mathew SJ
Am J Psychiatry; 2023 Mar; 180(3):190-199. PubMed ID: 36855876
[TBL] [Abstract][Full Text] [Related]
3. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
4. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
[TBL] [Abstract][Full Text] [Related]
5. Keeping up with the clinical advances: depression.
Ragguett RM; Tamura JK; McIntyre RS
CNS Spectr; 2019 Aug; 24(S1):25-37. PubMed ID: 31248466
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
Thomas SJ; Shin M; McInnis MG; Bostwick JR
Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
[TBL] [Abstract][Full Text] [Related]
7. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.
Lundberg J; Cars T; Lööv SÅ; Söderling J; Sundström J; Tiihonen J; Leval A; Gannedahl A; Björkholm C; Själin M; Hellner C
JAMA Psychiatry; 2023 Feb; 80(2):167-175. PubMed ID: 36515938
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
Kryst J; Kawalec P; Pilc A
Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
[No Abstract] [Full Text] [Related]
9. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.
Kumari S; Chaudhry HA; Sagot A; Doumas S; Abdullah H; Alcera E; Solhkhah R; Afzal S
Cureus; 2024 Feb; 16(2):e53987. PubMed ID: 38476783
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
[TBL] [Abstract][Full Text] [Related]
11. Next generation antidepressants with novel mechanisms for treatment resistant depression.
Chen MH; Tu PC; Su TP
Prog Brain Res; 2023; 278():149-168. PubMed ID: 37414491
[TBL] [Abstract][Full Text] [Related]
12. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
[TBL] [Abstract][Full Text] [Related]
14. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study.
Denee T; Kerr C; Ming T; Wood R; Tritton T; Middleton-Dalby C; Massey O; Desai M
J Psychiatr Res; 2021 Jul; 139():172-178. PubMed ID: 34077893
[TBL] [Abstract][Full Text] [Related]
15. Have Effective Antidepressants Finally Arrived? Developments in Major Depressive Disorder Therapy.
Thase ME
J Clin Psychiatry; 2023 Aug; 84(4):. PubMed ID: 37585245
[TBL] [Abstract][Full Text] [Related]
16. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
[TBL] [Abstract][Full Text] [Related]
18. Esketamine: A Novel Option for Treatment-Resistant Depression.
Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
[No Abstract] [Full Text] [Related]
19. An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depression.
Wu B; Cai Q; Sheehan JJ; Benson C; Connolly N; Alphs L
PLoS One; 2019; 14(8):e0220763. PubMed ID: 31393922
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.
Vecera CM; C Courtes A; Jones G; Soares JC; Machado-Vieira R
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
